The capacity of the non-nucleoside reverse transcriptase inhibitor efavirenz to induce either liver CYP3A4 or intestinal CYP3A4, or both, as well as intestinal P-glycoprotein, was evaluated in healthy volunteers during and after a 10-day treatment course with two different daily doses.
Cohorts of 12 healthy subjects were randomized (2:1) to receive eitherefavirenz or placebo orally for 10 days. The first cohort received 200 mg efavirenz and the second cohort received 400 mg efavirenz daily. Liver CYP3A4 activity was evaluated on 9 different occasions with use of the erythromycin breath test (ERMBT). Intestinal biopsyspecimens were obtained before the first dose of efavirenz and on the day after administration of the last dose to measure intestinal CYP3A4 and P-glycoprotein contents by immunoblotting. Efavirenz plasma levels were measured by HPLC, and pharmacokinetic parameters were determined by standard noncompartmental methods.
Efavirenz significantly increased the mean ERMBT result in a dose- andtime-dependent manner, with a 55% mean induction at 400 mg and a 33% mean induction at 200 mg (P < .01, compared with placebo for each treatment). The efavirenz AUC on day 10 correlated with the magnitude of induction (day 11/day 1 ERMBT ratio) when the two dose groups were combined (r = 0.509; P = .04). In contrast, efavirenz treatment had no detectable effect on intestinal CYP3A4 or P-glycoprotein.
Efavirenz is an inducer of liver CYP3A4 in healthy volunteesrs, and interpatient differences in magnitude of induction is partly explained by variation in systemic drug exposure. However, efavirenz did not appear to induce intestinal CYP3A4 or intestinal P-glycoprotein. These results suggest that drug interactions caused by induction of CYP3A4 can be liver specific.
Clinical Pharmacology & Therapeutics (2002) 72, 1–9;doi: 10.1067/mcp.2002.124519